| |
| |
|
| Insider
Information: |
Manning Paul B |
| Relationship: |
Director, 10% Owner |
| City: |
Allegan |
| State: |
MI |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
11,174,330 |
|
|
Indirect Shares
|
32,467,868 |
|
|
| Direct
Value |
$52,210,001 |
|
|
|
Indirect Value
|
$51,460,047 |
|
|
| Total
Shares |
43,642,198 |
|
|
| Total
Value |
$103,670,049 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
10
|
0
|
|
Stock
price went up :
|
7
|
0
|
| Stock
price went down : |
3
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
2.3
|
0.0
|
| Percentage
Gain/Loss : |
 32.2%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Avexis, Inc. |
AVXS |
Former 10% Owner, Dire... |
2018-05-15 |
0 |
2018-05-15 |
0 |
Premium* |
|
|
Dova Pharmaceuticals, Inc. |
DOVA |
Director, 10% Owner |
2019-11-12 |
0 |
2019-11-12 |
0 |
Premium* |
|
|
Verrica Pharmaceuticals Inc. |
VRCA |
Director, 10% Owner |
2023-07-24 |
7,851,128 |
2023-07-24 |
7,738,353 |
Premium* |
|
|
Taysha Gene Therapies, Inc. |
TSHA |
10% Owner |
2022-10-31 |
1,642,202 |
2023-11-17 |
23,517,778 |
Premium* |
|
|
Acumen Pharmaceuticals, Inc. |
ABOS |
10% Owner |
2021-07-06 |
0 |
2021-07-06 |
657,985 |
Premium* |
|
|
Candel Therapeutics, Inc. |
CADL |
Director, 10% Owner |
2021-07-29 |
1,681,000 |
2021-07-29 |
553,752 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
54 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AVXS |
Avexis, Inc. |
Former 10% Owner |
– • – |
2018-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,106 |
228,752 |
0 |
- |
|
| AVXS |
Avexis, Inc. |
Former 10% Owner |
– • – |
2018-05-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(228,752) |
0 |
0 |
- |
|
| AVXS |
Avexis, Inc. |
Former 10% Owner |
– • – |
2018-05-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,226,453) |
0 |
0 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2018-06-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,389,534 |
256,634 |
0 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2018-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,754,783 |
7,754,783 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • • |
2020-09-28 |
4 |
A |
$0.00 |
$0 |
I/I |
5,295,307 |
2,020,102 |
0 |
- |
|
| ABOS |
Acumen Pharmaceuticals, I... |
10% Owner |
– – • |
2021-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
3,608,469 |
657,985 |
0 |
- |
|
| CADL |
Candel Therapeutics, Inc. |
Director |
– • – |
2021-07-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,232,910 |
553,752 |
0 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
10% Owner |
– – • |
2023-08-16 |
4 |
B |
$0.90 |
$14,820,000 |
I/I |
16,466,667 |
16,466,667 |
1.5 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
10% Owner |
– – • |
2023-11-17 |
4 |
B |
$1.63 |
$163,000 |
I/I |
100,000 |
16,566,667 |
1.5 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • • |
2022-10-31 |
4 |
B |
$2.00 |
$3,000,000 |
D/D |
1,500,000 |
1,642,202 |
3.92 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2022-07-05 |
4 |
B |
$2.10 |
$9,999,998 |
D/D |
4,761,904 |
13,651,128 |
3.92 |
% |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2023-07-24 |
4 |
B |
$5.02 |
$1,004,000 |
D/D |
200,000 |
7,851,128 |
3.92 |
% |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
Director |
– • • |
2018-12-20 |
4 |
B |
$6.17 |
$1,645,113 |
D/D |
266,631 |
12,754,454 |
3.92 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2020-08-13 |
4 |
B |
$6.41 |
$695,485 |
I/I |
108,500 |
1,415,719 |
2.25 |
% |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
Director |
– • • |
2018-12-21 |
4 |
B |
$6.44 |
$832,050 |
D/D |
128,500 |
12,882,954 |
3.92 |
- |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2020-08-14 |
4 |
B |
$6.51 |
$325,500 |
I/I |
50,000 |
1,465,719 |
2.25 |
% |
|
| VRCA |
Verrica Pharmaceuticals I... |
Director |
– • • |
2020-08-17 |
4 |
B |
$6.92 |
$41,520 |
I/I |
6,000 |
1,471,719 |
2.25 |
% |
|
| CADL |
Candel Therapeutics, Inc. |
Director |
– • – |
2021-07-29 |
4 |
B |
$7.30 |
$145,944 |
D/D |
20,000 |
56,000 |
2.39 |
- |
|
| CADL |
Candel Therapeutics, Inc. |
Director |
– • – |
2021-07-27 |
4 |
B |
$7.36 |
$264,834 |
D/D |
36,000 |
36,000 |
2.39 |
- |
|
| DOVA |
Dova Pharmaceuticals, Inc... |
Director |
– • • |
2019-03-07 |
4 |
B |
$7.48 |
$508,640 |
D/D |
68,000 |
12,950,954 |
3.92 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • • |
2022-02-02 |
4 |
B |
$7.77 |
$520,590 |
I/I |
67,000 |
22,000 |
2.25 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • • |
2022-02-02 |
4 |
B |
$7.77 |
$450,660 |
D/D |
58,000 |
92,202 |
3.92 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • • |
2022-02-03 |
4 |
B |
$7.84 |
$392,000 |
D/D |
50,000 |
142,202 |
3.92 |
- |
|
| TSHA |
Taysha Gene Therapies, In... |
Director |
– • • |
2022-02-03 |
4 |
B |
$7.84 |
$208,560 |
I/I |
26,602 |
2,091,704 |
2.25 |
- |
|
54 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
